UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
THERAVANCE, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
88338T104
(CUSIP Number)
Victoria A. Whyte
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
Telephone: +44 (0)208 047 5000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
July 30, 2013
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
|
CUSIP No. 88338T104
|
SCHEDULE 13D/A
|
Page 2 of 8
|
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
GlaxoSmithKline plc
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
SOURCE OF FUNDS
WC
|
||
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
|
||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
|
||
|
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
-0-
|
|
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
29,785,600 shares of Common Stock (See Items 5(a) and 5(b))
|
|
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
-0-
|
|
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
29,785,600 shares of Common Stock (See Items 5(a) and 5(b))
|
|
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
29,785,600 shares of Common Stock (See Item 5(a)) (1)
|
||
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
|
||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.96% of the shares of Common Stock (See Item 5(a))
|
||
|
14
|
TYPE OF REPORTING PERSON
CO
|
||
Footnotes:
(1) Shares of Common Stock are held of record by Glaxo Group Limited, an indirect wholly owned subsidiary of GlaxoSmithKline plc.
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page 3 of 8
|
Item 1. Security and Issuer.
This Amendment No. 3 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on December 9, 2010 (as amended by Amendment No. 1 filed on April 2, 2012 and Amendment No. 2 filed on May 16, 2012, the “Schedule 13D” and as amended by this Amendment No. 3, the “Statement”) with respect to the shares of common stock, par value $0.01 per share (the “Common Stock”), of Theravance, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principle executive offices are located at 901 Gateway Blvd., South San Francisco, CA 94080. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.
Item 2. Identity and Background.
The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 as attached to Amendment No. 1 in its entirety, and replacing it with Schedule 1 attached hereto.
Item 3. Source and Amount of Funds or Other Consideration.
The response set forth in Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following:
Glaxo Group Limited (“GGL”) expects to acquire 3,064,407 shares of Common Stock (the “Shares”) on August 2, 2013, pursuant to the 2013 Common Stock Purchase Agreement described below for total consideration of $111,850,855.50, which consideration is expected to be obtained from the working capital of GGL.
Item 4. Purpose of Transaction.
The response set forth in Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:
On July 30, 2013, GGL and GSK entered into a Common Stock Purchase Agreement with the Issuer (the “2013 Common Stock Purchase Agreement”), pursuant to which the Issuer agreed to issue and sell, and GGL agreed to purchase, the Shares for an aggregate purchase price of $111,850,855.50. The 2013 Common Stock Purchase Agreement was entered into pursuant to GSK’s right to purchase shares of Common Stock from the Issuer, in accordance with the Governance Agreement, (i) on a quarterly basis in the amount sufficient to maintain its ownership percentage in the Issuer taking into account the preceding quarter’s option exercise and equity vesting activity (the “Quarterly Right”) and (ii) upon the conversion or exchange of all or any portion of certain convertible indebtedness issued by the Issuer, each as more fully described above in this Item 4. The description of the 2013 Common Stock Purchase Agreement in this Item 4 is qualified in its entirety by reference to the full text of the 2013 Common Stock Purchase Agreement, a copy of which is attached as Exhibit 6 hereto and incorporated herein by reference.
In addition to the acquisitions described above, GSK has exercised its Quarterly Right pursuant to the Governance Agreement in each quarter following the execution of the 2012 Common Stock Purchase Agreement and acquired the amount of shares of Common Stock necessary to maintain its ownership percentage in the Issuer.
Item 5. Interest in Securities of the Issuer.
The response set forth in Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:
(a) GlaxoSmithKline plc beneficially owns 29,785,600 shares of Common Stock, which represents 26.96% of the 110,496,860 shares of Common Stock outstanding.
(b) Subject to the limitations described in Item 4 of this Statement, GlaxoSmithKline plc has the sole power to vote or direct the vote, and the sole power to dispose or to direct the disposition of all 29,785,600 shares of Common Stock described in Item 5(a).
(c) Except as described herein, no transactions in shares of Common Stock were effected during the past 60 days by GlaxoSmithKline plc.
(d) No person, other than GlaxoSmithKline plc, is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by GlaxoSmithKline plc.
(e) Not applicable.
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page 4 of 8
|
Item 7. Material To Be Filed As Exhibits.
The response set forth in Item 7 of the Schedule 13D is hereby amended by adding to the end of Item 7 the following:
Exhibit Name
|
6
|
Common Stock Purchase Agreement, dated July 30, 2013, by and among the Issuer, GGL and GSK, a copy of which is incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer on July 30, 2013.
|
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page 5 of 8
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
| GLAXOSMITHKLINE PLC | |
|
/s/ Simon Bicknell
By: Simon Bicknell
Title: Company Secretary (interim)
|
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page 6 of 8
|
SCHEDULE I
|
Name
|
Business Address
|
Principal Occupation or Employment
|
Citizenship
|
|
Board of Directors
|
|||
|
Sir Andrew Witty
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Executive Director and Chief Executive Officer
|
British
|
|
Simon Dingemans
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Executive Director and Chief Financial Officer
|
British
|
|
Dr. Moncef Slaoui
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Executive Director and
Chairman Global Research & Development and Vaccines
|
Moroccan, Belgian & US
|
|
Sir Christopher Gent
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chairman and Company Director
|
British
|
|
Professor Sir Roy Anderson
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
|
Dr. Stephanie Burns
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
US
|
|
Stacey Cartwright
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
|
Judy Lewent
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
US
|
|
Sir Deryck Maughan
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
|
Dr. Daniel Podolsky
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
US
|
|
Name
|
Business Address
|
Principal Occupation or Employment
|
Citizenship
|
|
Tom de Swaan
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
Dutch
|
|
Sir Robert Wilson
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
|
Lynn Elsenhans
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
US
|
|
Jing Ulrich
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
US
|
|
Hans Wijers
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
Dutch
|
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page 7 of 8
|
|
Corporate Executive Team
|
|||
|
Sir Andrew Witty
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chief Executive Officer
|
British
|
|
Simon Dingemans
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Executive Director and Chief Financial Officer
|
British
|
|
Dr. Moncef Slaoui
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Executive Director
Chairman Global Research & Development and Vaccines
|
Moroccan, Belgian & US
|
|
Simon Bicknell
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Senior Vice President, Governance, Ethics and Assurance and
Company Secretary (interim)
|
British
|
|
Deirdre Connelly
|
5 Crescent Drive,
Philadelphia, PA
19112
|
President, North America
Pharmaceuticals
|
US
|
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page 8 of 8
|
|
Abbas Hussain
|
150 Beach Road
22-00 Gateway West
189720
Singapore
|
President, Europe & Emerging Markets & Asia Pacific
|
British
|
|
William Louv
|
Five Moore Drive
PO Box 13398
Research Triangle Park
North Carolina 27709
|
Senior Vice President, Core Business Services
|
US
|
|
David Redfern
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chief Strategy Officer
|
British
|
|
Christophe Weber
|
Avenue Fleming, 20
B-1300 Wavre
Belgium
|
President, Vaccines
|
French
|
|
Claire Thomas
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Senior Vice President,
Human Resources
|
British
|
|
Philip Thomson
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Senior Vice President, Global Communications
|
British
|
|
Daniel Troy
|
5 Crescent Drive
Philadelphia, PA
19112
|
Senior Vice President & General Counsel
|
US
|
|
Dr. Patrick Vallance
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
President, Pharmaceuticals R&D
|
British
|
|
Emma Walmsley
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
President, Consumer Healthcare Worldwide
|
British
|
|
Roger Connor
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
President, Global Manufacturing & Supply
|
British
|